Académique Documents
Professionnel Documents
Culture Documents
DAFTAR PUSTAKA
20. Tan D, Chng WJ, Chou T, Nawarawong SY, Hwang SY, Chim CS, et al.
Management of multiple myeloma in Asia: resource-startified guidelines.
Lancet 2013;14:571-9.
21. Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et
al. Age and organ damage correlate with poor survival in myeloma
patients: Meta-analysis of 1435 individual patient data from 4 randomized
trials. Haematologica 2013;98:980-7.
22. Chanan-Khan AA, Giralt S. Importance of achieving a complete response
in multiple myeloma, and the impact of novel agents. J Clin Oncol.
2010;15(28):2612-24.
23. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi
FK, et al. Improved survival in multiple myeloma and the impact of novel
therapies. Blood. 2008;5(111):2516-20.
24. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al.
Complete response correlates with long-term progression-free and overall
survival in elderly myeloma treated with novel agents: analysis of 1175
patients. Blood. 2011;117:3025-31.
25. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma.
Blood. 2015;20:3076-84.
26. Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K,
et al. International uniform response criteria for multiple myeloma.
Leukemia. 2006;20:1467-73.
27. Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory
drugs action in the treatment of multiple myeloma. Acta Biochim Biophys
Sin. 2014;46(3):240-7.